<b>Background:</b> Soluble immune checkpoint molecules, including soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1), have emerged as potential minimally invasive biomarkers in non-small cell lung cancer (NSCLC). The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.